Jonas Jögi

Jonas Jögi

Auto-generated profile, based on publicly available information

Jonas Jögi

Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
RORik Ossenkoppele
Rik Ossenkoppele
ABAlexa Pichet Binette
Alexa Pichet Binette
CGColin Groot
Colin Groot
RSRuben Smith
Ruben Smith
OSOlof Strandberg
Olof Strandberg
OHOskar Hansson
Oskar Hansson
A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer’s disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A+) and tau PET-positive (T+) in the medial temporal lobe (A+TMTL+) and/or in the temporal neocortex (A+TNEO-T+) and compared them with A+T−and A−T−groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A+TNEO-T+(hazard ratio (HR) = 19.2, 95% confidence interval (CI) = 10.9–33.7), A+TMTL+(HR = 14.6, 95% CI = 8.1–26.4) and A+T−(HR = 2.4, 95% CI = 1.4–4.3) groups versus the A−T−(reference) group. Both A+TMTL+(HR = 6.0, 95% CI = 3.4–10.6) and A+TNEO-T+(HR = 7.9, 95% CI = 4.7–13.5) groups also showed faster clinical progression to mild cognitive impairment than the A+T−group. Linear mixed-effect models indicated that the A+TNEO-T+(β = −0.056 ± 0.005,T = −11.55,P < 0.001), A+TMTL+(β = −0.024 ± 0.005,T = −4.72,P < 0.001) and A+T−(β = −0.008 ± 0.002,T = −3.46,P < 0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A−T−(reference) group (allP < 0.001). Both A+TNEO-T+(P < 0.001) and A+TMTL+(P = 0.002) groups also progressed faster than the A+T−group. In summary, evidence of advanced Alzheimer’s disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3–5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.

18 September 2018 in JAMA
Verified
Journal Article
Closed access
PDF file
RORik Ossenkoppele
Rik Ossenkoppele
GRGil D. Rabinovici
Gil D. Rabinovici
RSRuben Smith
Ruben Smith
HCHanna Cho
Hanna Cho
MSMichael Schöll
Michael Schöll
OHOskar Hansson
Oskar Hansson
Importance The positron emission tomography (PET) tracer [18F]flortaucipir allows in vivo quantification of paired helical filament tau, a core neuropathological feature of Alzheimer disease (AD), but its diagnostic utility is unclear. Objective To examine the discriminative accuracy of [18F]flortaucipir for AD vs non-AD neurodegenerative disorders. Design, Setting, and Participants In this cross-sectional study, 719 participants were recruited from 3 dementia centers in South Korea, Sweden, and the United States between June 2014 and November 2017 (160 cognitively normal controls, 126 patients with mild cognitive impairment [MCI], of whom 65.9% were amyloid-β [Aβ] positive [ie, MCI due to AD], 179 patients with AD dementia, and 254 patients with various non-AD neurodegenerative disorders). Exposures The index test was the [18F]flortaucipir PET standardized uptake value ratio (SUVR) in 5 predefined regions of interest (ROIs). Cut points for tau positivity were determined using the mean +2 SDs observed in controls and Youden Index for the contrast AD dementia vs controls. Main Outcomes and Measures The reference standard was the clinical diagnosis determined at the specialized memory centers. In the primary analysis, the discriminative accuracy (ie, sensitivity and specificity) of [18F]flortaucipir was examined for AD dementia vs all non-AD neurodegenerative disorders. In secondary analyses, the area under the curve (AUC) of [18F]flortaucipir SUVR was compared with 3 established magnetic resonance imaging measures (hippocampal volumes and AD signature and whole-brain cortical thickness), and sensitivity and specificity of [18F]flortaucipir in MCI due to AD vs non-AD neurodegenerative disorders were determined. Results Among 719 participants, the overall mean (SD) age was 68.8 (9.2) years and 48.4% were male. The proportions of patients who were amyloid-β positive were 26.3%, 65.9%, 100%, and 23.8% among cognitively normal controls, patients with MCI, patients with AD dementia, and patients with non-AD neurodegenerative disorders, respectively. [18F]flortaucipir uptake in the medial-basal and lateral temporal cortex showed 89.9% (95% CI, 84.6%-93.9%) sensitivity and 90.6% (95% CI, 86.3%-93.9%) specificity using the threshold based on controls (SUVR, 1.34), and 96.8% (95% CI, 92.0%-99.1%) sensitivity and 87.9% (95% CI, 81.9%-92.4%) specificity using the Youden Index–derived cutoff (SUVR, 1.27) for distinguishing AD dementia from all non-AD neurodegenerative disorders. The AUCs for all 5 [18F]flortaucipir ROIs were higher (AUC range, 0.92-0.95) compared with the 3 volumetric MRI measures (AUC range, 0.63-0.75; all ROIsP < .001). Diagnostic performance of the 5 [18F]flortaucipir ROIs were lower in MCI due to AD (AUC range, 0.75-0.84). Conclusions and Relevance Among patients with established diagnoses at a memory disorder clinic, [18F]flortaucipir PET was able to discriminate AD from other neurodegenerative diseases. The accuracy and potential utility of this test in patient care require further research in clinically more representative populations.

1 August 2020 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
ALAntoine Leuzy
Antoine Leuzy
RSRuben Smith
Ruben Smith
RORik Ossenkoppele
Rik Ossenkoppele
ASAlexander Santillo
Alexander Santillo
EBEdilio Borroni
Edilio Borroni
OHOskar Hansson
Oskar Hansson
Alzheimer disease (AD) is characterized by deposition of amyloid β (Aβ) in senile plaques and hyperphosphorylated tau in neurofibrillary tangles,1 which consist mainly of paired helical filaments (PHFs) comprising a mixture of 3- to 4-repeat tau isoforms.2,3 Tau pathology is also seen in various non-AD neurodegenerative disorders, including progressive supranuclear palsy and other variants of frontotemporal lobar degeneration.4 Tau deposits in these disorders, however, differ from the AD-type PHFs consisting of 3- to 4 repeat tau isoforms.5 In AD, cortical neurofibrillary neurotangles are closely associated with neurodegeneration and onset of cognitive impairment.6

16 July 2017 in Brain
Verified
Journal Article
Open access
PDF file
MSMichael Schöll
Michael Schöll
RORik Ossenkoppele
Rik Ossenkoppele
OSOlof Strandberg
Olof Strandberg
SPSebastian Palmqvist
Sebastian Palmqvist
TSThe Swedish BioFINDER study
The Swedish BioFINDER study
OHOskar Hansson
Oskar Hansson
Patients with Alzheimer’s disease can present with different clinical phenotypes. Individuals with late-onset Alzheimer’s disease (>65 years) typically present with medial temporal lobe neurodegeneration and predominantly amnestic symptomatology, while patients with early-onset Alzheimer’s disease (<65 years) exhibit greater neocortical involvement associated with a clinical presentation including dyspraxia, executive dysfunction, or visuospatial impairment. We recruited 20 patients with early-onset Alzheimer’s disease, 21 with late-onset Alzheimer’s disease, three with prodromal early-onset Alzheimer’s disease and 13 with prodromal late-onset Alzheimer’s disease, as well as 30 cognitively healthy elderly controls, that had undergone 18F-AV-1451 tau positron emission tomography and structural magnetic resonance imaging to explore whether early- and late-onset Alzheimer’s disease exhibit differential regional tau pathology and atrophy patterns. Strong associations of lower age at symptom onset with higher 18F-AV-1451 uptake were observed in several neocortical regions, while higher age did not yield positive associations in neither patient group. Comparing patients with early-onset Alzheimer’s disease with controls resulted in significantly higher 18F-AV-1451 retention throughout the neocortex, while comparing healthy controls with late-onset Alzheimer’s disease patients yielded a distinct pattern of higher 18F-AV-1451 retention, predominantly confined to temporal lobe regions. When compared against each other, the early-onset Alzheimer’s disease group exhibited greater uptake than the late-onset group in prefrontal and premotor, as well as in inferior parietal cortex. These preliminary findings indicate that age may constitute an important contributor to Alzheimer’s disease heterogeneity highlighting the potential of tau positron emission tomography to capture phenotypic variation across patients with Alzheimer’s disease.

25 July 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
NMNiklas Mattsson
Niklas Mattsson
MSMichael Schöll
Michael Schöll
OSOlof Strandberg
Olof Strandberg
RSRuben Smith
Ruben Smith
SPSebastian Palmqvist
Sebastian Palmqvist
OHOskar Hansson
Oskar Hansson
To elucidate the relationship between cerebrospinal fluid (CSF) total‐tau (T‐tau) and phosphorylated tau (P‐tau) with the tau PET ligand 18 F‐AV‐1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T‐tau and P‐tau were highly correlated ( R = 0.92, P < 0.001), but they were only moderately associated with retention of 18 F‐AV‐1451, and mainly in demented AD patients. 18 F‐AV‐1451, but not CSF T‐tau or P‐tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18 F‐AV‐1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though 18 F‐AV‐1451 retention was always increased at this disease stage. We conclude that CSF T‐tau and P‐tau mainly behave as biomarkers of “disease state”, since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, 18 F‐AV‐1451 is a biomarker of “disease stage”, since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.

6 October 2016 in Movement Disorders
Verified
Journal Article
Open access
PDF file
RSRuben Smith
Ruben Smith
MSMartin Schain
Martin Schain
CNChrister Nilsson
Christer Nilsson
OSOlof Strandberg
Olof Strandberg
TOTomas Olsson
Tomas Olsson
OHOskar Hansson
Oskar Hansson
Background: Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work‐up of PSP.Methods: Regional tau accumulation was studied using 18F‐AV‐1451 PET in 11 patients with PSP and 11 age‐matched healthy controls in the Swedish BioFinder study.Results: 18F‐AV‐1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r = .43–.78, P < .05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating scale and standard uptake volume ratios in the globus pallidus (r = .74, P < .05). However, no 18F‐AV‐1451 retention was observed in the cerebral cortex or white matter of either PSP patients or controls, and autoradiography did not reveal any specific binding of AV‐1451 to PSP tau aggregates.Conclusion: We found higher 18F‐AV‐1451 retention in the basal ganglia of PSP patients when compared with healthy elderly controls, but also increases with age in both controls and patients. As a result of the overlap in retention between diagnostic groups and the age‐dependent increase present also in controls, 18F‐AV‐1451 PET might not reliably distinguish individual patients with PSP from controls. However, further studies are needed to evaluate whether 18F‐AV‐1451 PET might be useful as a progression marker in clinical PSP trials. © The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.